Diamedica's platform
technology has the potential to revolutionize the treatment
of Type II diabetes, offering truly effective therapeutics
for this widespread and poorly treated disorder. The company
is based on discoveries by Dr. Wayne Lautt at the University
of Manitoba.
Miraculins
Inc. is a publicly traded proteomics based research company
dedicated to the discovery and development of therapeutics
and diagnostics for human disorders. The Company's
research strategy is designed to identify biomarkers (proteins
and peptides) with a focus on select cancers.
Kane
Biotech Inc. is a publicly traded biotechnology company
established around a patent protected technology to find
compounds which prevent or disrupt biofilms in medical
and industrial applications.
Medicure
Inc. is a biotechnology company focused on the development
of therapies for unmet cardiovascular needs. Medicure's
drug discovery and development programs are advancing
several products towards the market. The lead product,
MC-1, is currently in clinical testing for reduction of
injury due to heart attacks and cardiovascular procedures.
In December 2001, Medicure graduated from the Genesys
Venture Incubator and now has totally independent operations.
Mantex Biotech Inc.
was established in 1997. The company is developing effective
treatments for cardiac hypertrophy and heart failure.
In 1999, Mantex's technology was sold to the US biotechnology
firm Myogen Inc.
Cronus
BioPharma Inc.
Cronus
is a private spin-out from the University of Manitoba
dedicated to the discovery and development of products
for the treatment of asthma. The company was incorporated,
financed and managed through the GVI structure.
